Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
To determine the safety of prophylaxis with Tinzaparin low molecular weight heparin in
primary brain tumor patients. 2. To determine the incidence of deep venous thrombosis or
pulmonary embolism in brain tumor patients who will be receiving Tinzaparin as primary
prophylaxis. 3. To determine the overall survival of patients with malignant glioma who
receive Tinzaparin. 4. To determine the bone density before and after prophylactic
Tinzaparin.